Full Generic Medicine Info
Dosage/Direction for Use

Anovulatory infertility
Adult: 50 mg once daily for 5 days, starting at any time if there is no uterine bleeding or on the 5th day of the menstrual cycle. If ovulation does not occur w/in 5-10 days, a 2nd course of 100 mg once daily for 5 days may be given, starting as early as 30 days after the previous course. Max: 3 courses.
Hepatic impairment: Contraindicated.
May be taken with or without food.
Abnormal uterine bleeding of unknown origin, ovarian cyst or enlargement not due to polycystic ovarian syndrome, organic intracranial lesion (e.g. pituitary tumour), uncontrolled thyroid or adrenal dysfunction. Active liver disease or history of hepatic impairment. Pregnancy.
Special Precautions
Patient w/ uterine fibroids, polycystic ovarian syndrome (PCOS). Lactation. Patient Counselling This drug may cause visual disturbances, dizziness, and lightheadedness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor serum oestrogen prior to therapy. Perform pelvic exam and endometrial biopsy before each course and pregnancy test prior to repeat courses. Monitor for ovulation through basal body temp, ultrasound, serum progesterone, oestradiol, and urinary LH. Assess signs and symptoms of ovarian hyperstimulation syndrome (OHSS).
Adverse Reactions
Significant: Mild to moderate OHSS, visual disturbance (e.g. blurring, scotomata, diplopia, photophobia), endometriosis, ovarian enlargement and cyst formation, risk of multiple or ectopic pregnancy. Rarely, risk of borderline or invasive ovarian cancer. Nervous: Headache, convulsion, restlessness, insomnia, dizziness, vertigo, lightheadedness, depression, nervous tension, fatigue, insomia. GI: Nausea, vomiting, constipation, diarrhoea, increased appetite. Genitourinary: Increased urinary frequency and volume, vag dryness, menorrhagia, uterine haemorrhage, endometriosis. Endocrine: Vasomotor flushes, heavier menses, hypertriglyceridemia, wt gain. Hepatic: Jaundice. Dermatologic: Urticaria, rash, dermatitis, hair loss and dryness. Others: Breast discomfort.
Potentially Fatal: Severe OHSS manifesting as gross ovarian enlargement, pericardial effusion, severe abdominal pain, ascites, dyspnoea, acute resp distress syndrome, hypotension, tachycardia, thromboembolism, hypovolemic shock, and haemoconcentration.
Symptoms: Nausea, vomiting, vasomotor flashes, blurring of vision, scotomata, ovarian enlargement w/ pelvic or abdominal pain. Management: Supportive treatment. Perform GI decontamination.
Drug Interactions
May enhance adverse effect of ospemifene.
Clomifene is a nonsteroidal compound that has both oestrogenic and anti-oestrogenic effects. It stimulates ovulation by inhibiting the negative feedback effect of oestrogens at receptor sites in the hypothalamus and pituitary, thereby increasing hypothalamic GnRH secretion w/ subsequent release of pituitary FSH and LH.
Onset: 5-10 days.
Absorption: Readily absorbed from the GI tract. Time to peak plasma concentration: Approx 6 hr.
Metabolism: Metabolised in the liver; undergoes enterohepatic recirculation.
Excretion: Via faeces (42%) and urine (8%). Elimination half-life: Approx 5 days.
Oral: Store below 25°C. Protect from light, heat, and excessive humidity. Use appropriate personal protective equipment (e.g. gloves) for receiving, handling, admin and disposal.
CIMS Class
Trophic Hormones & Related Synthetic Drugs
ATC Classification
G03GB02 - clomifene ; Belongs to the class of synthetic agents used as ovulation stimulants.
Disclaimer: This information is independently developed by CIMS based on clomifene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in